(Q40930271)

24 September 2017

0 references

High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma (English)

1 reference

24 September 2017

Wei Zhang

1

1 reference

24 September 2017

Huanran Chen

series ordinal

2

1 reference

24 September 2017

Shengqing Lv

series ordinal

3

1 reference

24 September 2017

Hui Yang

series ordinal

4

1 reference

24 September 2017

publication date

17 May 2015

1 reference

24 September 2017

published in

Molecular Neurobiology

1 reference

24 September 2017

volume

53

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

2354-2360

1 reference

Glioblastoma and other malignant gliomas: a clinical review.

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Malignant glioma: lessons from genomics, mouse models, and stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Molecular prognostic factors in glioblastoma: state of the art and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

MGMT testing--the challenges for biomarker-based glioma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

CD133-targeted niche-dependent therapy in cancer: a multipronged approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

CD133: a cancer stem cells marker, is used in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

CD133/prominin1 is prognostic for GBM patient's survival, but inversely correlated with cysteine cathepsins' expression in glioblastoma derived spheroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Stem cell marker CD133 affects clinical outcome in glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Correlation of altered expression of the autophagy marker LC3B with poor prognosis in astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Endocrine aspects of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Telomere profiling: toward glioblastoma personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Cancer stem cells: the promise and the potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9187-1

Clinical value of CD133 and nestin in patients with glioma: a population-based study

21 January 2018

1 reference

12 December 2020

Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas

1 reference

12 December 2020

Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review

1 reference

12 December 2020

AEG-1 expression correlates with CD133 and PPP6c levels in human glioma tissues

1 reference

12 December 2020

Expression of the lysosomal-associated membrane protein-1 (LAMP-1) in astrocytomas

1 reference

12 December 2020

Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis

1 reference

12 December 2020

The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

CFIm25 links alternative polyadenylation to glioblastoma tumour suppression.

1 reference

12 December 2020

Glioblastoma stem cells: a new target for metformin and arsenic trioxide.

1 reference

12 December 2020

Cancer stem cells: implications for cancer therapy.

1 reference

12 December 2020

10.1007/S12035-015-9187-1

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

1035092386

0 references

1 reference